BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 35409404)

  • 1. Stromal Factors as a Target for Immunotherapy in Melanoma and Non-Melanoma Skin Cancers.
    Fujimura T
    Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of Immunosuppressive Cells as a Target for Immunotherapies in Melanoma and Non-Melanoma Skin Cancers.
    Fujimura T; Aiba S
    Biomolecules; 2020 Jul; 10(8):. PubMed ID: 32707850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma.
    Uryvaev A; Passhak M; Hershkovits D; Sabo E; Bar-Sela G
    Med Oncol; 2018 Jan; 35(3):25. PubMed ID: 29388007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
    Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammatory cell infiltrates in advanced metastatic uveal melanoma.
    Krishna Y; McCarthy C; Kalirai H; Coupland SE
    Hum Pathol; 2017 Aug; 66():159-166. PubMed ID: 28655639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
    Mushtaq MU; Papadas A; Pagenkopf A; Flietner E; Morrow Z; Chaudhary SG; Asimakopoulos F
    J Immunother Cancer; 2018 Jul; 6(1):65. PubMed ID: 29970158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development.
    Figueiredo CR; Kalirai H; Sacco JJ; Azevedo RA; Duckworth A; Slupsky JR; Coulson JM; Coupland SE
    J Pathol; 2020 Apr; 250(4):420-439. PubMed ID: 31960425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression.
    Andersen R; Borch TH; Draghi A; Gokuldass A; Rana MAH; Pedersen M; Nielsen M; Kongsted P; Kjeldsen JW; Westergaard MCW; Radic HD; Chamberlain CA; Hölmich LR; Hendel HW; Larsen MS; Met Ö; Svane IM; Donia M
    Ann Oncol; 2018 Jul; 29(7):1575-1581. PubMed ID: 29688262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasminogen Activating Inhibitor-1 Might Predict the Efficacy of Anti-PD1 Antibody in Advanced Melanoma Patients.
    Ohuchi K; Kambayashi Y; Hidaka T; Fujimura T
    Front Oncol; 2021; 11():798385. PubMed ID: 34912726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-associated macrophages in skin: How to treat their heterogeneity and plasticity.
    Fujimura T; Kakizaki A; Furudate S; Kambayashi Y; Aiba S
    J Dermatol Sci; 2016 Sep; 83(3):167-73. PubMed ID: 27291068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study).
    Nakamura Y; Namikawa K; Yoshikawa S; Kiniwa Y; Maekawa T; Yamasaki O; Isei T; Matsushita S; Nomura M; Nakai Y; Fukushima S; Saito S; Takenouchi T; Tanaka R; Kato H; Otsuka A; Matsuya T; Baba N; Nagase K; Inozume T; Fujimoto N; Kuwatsuka Y; Onishi M; Kaneko T; Onuma T; Umeda Y; Ogata D; Takahashi A; Otsuka M; Teramoto Y; Yamazaki N
    ESMO Open; 2021 Dec; 6(6):100325. PubMed ID: 34839104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for melanoma.
    Cuevas LM; Daud AI
    Semin Cutan Med Surg; 2018 Jun; 37(2):127-131. PubMed ID: 30040090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy.
    Lee N; Zakka LR; Mihm MC; Schatton T
    Pathology; 2016 Feb; 48(2):177-87. PubMed ID: 27020390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.
    Lepletier A; Madore J; O'Donnell JS; Johnston RL; Li XY; McDonald E; Ahern E; Kuchel A; Eastgate M; Pearson SA; Mallardo D; Ascierto PA; Massi D; Merelli B; Mandala M; Wilmott JS; Menzies AM; Leduc C; Stagg J; Routy B; Long GV; Scolyer RA; Bald T; Waddell N; Dougall WC; Teng MWL; Smyth MJ
    Clin Cancer Res; 2020 Jul; 26(14):3671-3681. PubMed ID: 32345648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current opinions in immune checkpoint inhibitors rechallenge in solid cancers.
    Gobbini E; Charles J; Toffart AC; Leccia MT; Moro-Sibilot D; Giaj Levra M
    Crit Rev Oncol Hematol; 2019 Dec; 144():102816. PubMed ID: 31707222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma.
    Hogan SA; Courtier A; Cheng PF; Jaberg-Bentele NF; Goldinger SM; Manuel M; Perez S; Plantier N; Mouret JF; Nguyen-Kim TDL; Raaijmakers MIG; Kvistborg P; Pasqual N; Haanen JBAG; Dummer R; Levesque MP
    Cancer Immunol Res; 2019 Jan; 7(1):77-85. PubMed ID: 30425105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Local immune response in cutaneous basal cell carcinoma.
    Omland SH
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profiling Cancer-Associated Fibroblasts in Melanoma.
    Papaccio F; Kovacs D; Bellei B; Caputo S; Migliano E; Cota C; Picardo M
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
    Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
    IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma.
    Wong PF; Wei W; Gupta S; Smithy JW; Zelterman D; Kluger HM; Rimm DL
    J Immunother Cancer; 2019 Jul; 7(1):194. PubMed ID: 31337426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.